|6/26/2020||Orion publishes Half-Year Financial Report for January-June 2020 on Friday 17 July 2020|
|6/26/2020||Distribution of Zoetis’ products in Sweden, Denmark and Norway by Orion to end after 2020|
|6/4/2020||Orion is developing an immuno-oncology (IO) drug discovery platform in the national research and innovation consortium Cancer IO|
|5/20/2020||Sales of darolutamide started in the EU and Japan – Orion receives total of EUR 28 million milestones|
Orion published Half-Year Financial Report for January-June 2020 on Friday, 17 July 2020. The report and related presentation material and webcast recording are available here.
The 2020 Annual General Meeting of Orion was held on Wednesday, 6 May 2020. The decisions and related material are available here.
|7/28/2020||Orion’s phase 3 REFALS trial evaluating the efficacy of oral levosimendan in treatment of ALS patients did not reach its pre-specified endpoints|
|7/17/2020||Orion Group Half-Year Financial Report 1-6/2020|
|7/17/2020||Orion Corporation's financial reporting and Annual General Meeting in 2021|
|7/14/2020||191,501 Orion Corporation A shares converted into B shares|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.